Trial Profile
Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- 22 Aug 2023 Planned End Date changed from 31 May 2023 to 30 Apr 2024.
- 22 Aug 2023 Planned primary completion date changed from 31 May 2023 to 30 Apr 2024.
- 26 Aug 2022 Planned End Date changed from 31 May 2022 to 31 May 2023.